LURASIDONE HYDROCHLORIDE (lurasidone hydrochloride) by Jubilant Therapeutics is unclear. Approved for adolescent patients (13 to 17 years) with schizophrenia [see clinical studies ()], schizophrenia, schizophrenia. First approved in 2023.
Drug data last refreshed 20h ago
unclear. However, its efficacy in schizophrenia and other indication could be mediated through a combination of central dopamine D2 and serotonin Type 2 (5HT2A) receptor antagonism.
Worked on LURASIDONE HYDROCHLORIDE at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.